Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular morbidity and mortality. We sought to evaluate the risk of concomitant coronary artery disease (CAD) in patients with symptomatic PAD versus PAD without diagnosed CAD, and whether ticagrelor was superior to clopidogrel in reducing that risk. The EUCLID trial randomized 13,885 patients with PAD to antithrombotic monotherapy with ticagrelor or clopidogrel. CAD was defined as prior myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG) surgery. Median follow-up was 30 months. Among 4032 (29%) patients with PAD and CAD, 63% had prior MI, 54% prior PCI, and 38% prior CABG. After adjustment for baseline characteristics, patients with PAD and CAD had significantly higher rates of the primary endpoint (cardiovascular death/MI/stroke, 15.3% vs 8.9%, hazard ratio (HR) 1.50, 95% CI: 1.13-1.99; p=0.005), but no statistically significant increase in acute limb ischemia (HR 1.28, 95% CI: 0.57-2.85; p=0.55) or major bleeding (HR 1.10, 95% CI: 0.49-2.48; p=0.81) versus PAD without CAD. Among patients with PAD and CAD, there was no differential treatment effect between ticagrelor versus clopidogrel for the primary efficacy endpoint (HR 1.02, p=0.84), acute limb ischemia (HR 1.03, 95% CI: 0.63-1.69; p=0.89), or major bleeding (HR 1.06, 95% CI: 0.66-1.69; p=0.81). There was a statistically significant interaction between prior coronary stent placement and study treatment (p=0.03) with a numerical reduction in the primary efficacy endpoint with ticagrelor versus clopidogrel (13.8% vs 16.8%, HR 0.82, p=0.09). Patients with PAD and prior CAD had higher composite rates of cardiovascular death, MI, and ischemic stroke versus PAD without diagnosed CAD. There were no significant differences between ticagrelor and clopidogrel in cardiovascular events or major bleeding.
Introduction
Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular morbidity and mortality and impaired quality of life. Many patients with PAD have clinical evidence of concomitant coronary artery disease (CAD) or a prior history of coronary revascularization and are defined as having polyvascular disease. 1, 2 Patients with polyvascular disease have a worse prognosis compared with patients with disease in a single arterial bed. 3 Accordingly, intensive secondary prevention strategies are a mainstay of treatment.
Antiplatelet therapy reduces the risk of myocardial infarction (MI), stroke, and cardiovascular death in patients with PAD and CAD. 4 Among patients with PAD, CAD, or prior stroke in the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events) trial, monotherapy with clopidogrel versus aspirin reduced the risk of cardiovascular events, with the PAD subgroup showing the most favorable response to clopidogrel. 5 Ticagrelor is an oral, reversibly bound inhibitor of the P2Y12 receptor that has a greater and more consistent inhibition of platelet aggregation than clopidogrel. 6 Ticagrelor was shown to be more effective than clopidogrel in the setting of acute coronary syndrome (ACS) and versus placebo in patients with prior MI. 7, 8 Subgroup analyses of patients with CAD (ACS and prior MI) and PAD suggest that the absolute benefit of ticagrelor versus clopidogrel 9 or placebo 10 was amplified in patients with concomitant CAD and PAD.
The effect of ticagrelor versus clopidogrel was most recently evaluated in the EUCLID (Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease) trial, 11 which enrolled patients with symptomatic PAD. In EUCLID, monotherapy with ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events. Sensitivity analysis of the primary endpoint revealed a nominally significant interaction (p=0.03) in the subgroup of patients with coronary stent implantation prior to randomization. 11 Patients with prior coronary stent implantation appeared to derive a marginal benefit from ticagrelor versus clopidogrel. 11 In this report, two major hypotheses were tested: (1) the risk of cardiovascular, limb, and bleeding events are higher in patients with PAD and CAD than PAD without diagnosed CAD, and (2) monotherapy with ticagrelor would be superior to clopidogrel in the subgroup of patients with PAD and CAD included in the EUCLID trial.
Methods
EUCLID was a prospective, multicenter, randomized, double-blind, event-driven study. It was approved by the institutional review committee of each participating site as well as by appropriate national ethics committees. All patients gave written informed consent. The details of the trial design 12 and the main results have been published previously. 11 Briefly, 13,885 patients ≥ 50 years of age with lower extremity PAD were randomly assigned to receive monotherapy with either ticagrelor (90 mg twice daily) or clopidogrel (75 mg once daily) and followed for a median of 30 months.
This report includes the 4032 (29%) patients with CAD who were identified in the EUCLID study. To fulfill criteria for CAD, patients had a history of prior MI, prior percutaneous coronary intervention (PCI), or prior coronary artery bypass graft (CABG) surgery as reported by the site investigator on the case report form.
Endpoints
The primary efficacy endpoint was time from randomization to first occurrence of any event in the composite of adjudicated cardiovascular death, MI, or ischemic stroke. Secondary endpoints included the primary composite endpoint plus acute limb ischemia (ALI), cardiovascular death alone, MI, all-cause mortality, the primary composite endpoint including all-cause stroke, ALI alone, time to lower extremity revascularization, and time to any revascularization. The primary safety endpoint was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. The components of the primary efficacy endpoint, the primary safety endpoint, and all hospitalizations for ALI were adjudicated by an independent clinical events classification committee.
Hospitalization for ALI was not considered a standard endpoint at the time of protocol development. However, the protocol was amended in December 2013 to collect source data for all hospitalizations for PAD, peripheral revascularization, and amputation. Trained adjudicators, while blinded to treatment assignment, reviewed all information to determine whether patients had ALI defined as a hospitalization involving a rapid or sudden decrease in limb perfusion and either (1) a new pulse deficit, rest pain, pallor, paresthesia, or paralysis; or (2) confirmation of arterial obstruction by limb hemodynamics (ankle or toe pressure), imaging, intraoperative findings, or pathological evaluation.
Statistical analysis
The primary and secondary efficacy endpoints were analyzed using the intention-to-treat approach and were performed on the full analysis set consisting of all patients randomized to the study drug, irrespective of study drug adherence or withdrawal of consent. Patients who withdrew consent to participate in the study were included up to the date of their study termination with the exception of an analysis of all-cause mortality that used information from all patients for whom vital status could be determined via publically available records. The safety analysis set included all patients who received at least one dose of study drug while on treatment, defined as within 7 days of the last dose of study drug.
The primary and secondary endpoints were analyzed in the population of patients with a medical history of CAD in time-to-event analyses in a Cox proportional hazards model with a factor for treatment group. Unadjusted p-values and confidence intervals (CIs) for the hazard ratios (HRs) were based on the Wald statistic. Kaplan-Meier estimates of the cumulative proportion of patients with events were calculated and plotted.
The p-values for differences between baseline characteristics were calculated using chi-squared (cell size ≥ 5) and Fisher's exact (cell size < 5) tests for categorical variables, and Wilcoxon's test for continuous variables if the assumption for normality of distribution of the continuous variable was not met. Otherwise, continuous measures were tested using the t-test for two groups. Adjusted analyses for the primary composite endpoint, components of the primary composite endpoint, ALI, and major bleeding (using baseline variables shown in Table 1 ) were performed to determine whether patients with a medical history of CAD had higher rates of cardiovascular and acute limb events when compared with patients who did not. SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA) was used for all analyses and all tests were two-sided.
Results
A total of 13,885 participants with symptomatic PAD were randomized in the EUCLID trial, including 4032 (29%) participants with concomitant CAD (Figure 1 ). Of these, 2522 (62.5%) had prior MI, 2173 (53.9%) prior PCI, and 1536 (38.1%) prior CABG.
Profile of PAD and CAD
Patients with PAD and CAD were older, more frequently male, and heavier compared with patients without CAD ( Table 1) . A history of stroke, transient ischemic attack, carotid stenosis, diabetes mellitus, hypertension, and hyperlipidemia were reported more frequently in patients with PAD and CAD compared with PAD without diagnosed CAD. A higher proportion of patients with PAD and CAD were enrolled based on prior lower extremity revascularization (60.6% vs 55.1% with PAD without diagnosed CAD; p < 0.001). Prior amputation at baseline was less common in patients with PAD and CAD than PAD without diagnosed CAD (4.9% vs 7.3%; p < 0.001). Patients with prior CAD were also more commonly treated at baseline with cardioprotective medications including aspirin, clopidogrel, statins, and angiotensin converting enzyme inhibitors or angiotensin receptor blockers prior to participation in the study, as compared with those with no medical history of CAD. Conversely, use of cilostazol was more common in PAD without diagnosed CAD (Table 1) .
Outcomes in PAD and CAD
The unadjusted composite rate of cardiovascular death, MI, or ischemic stroke was 15.3% in patients with PAD and CAD and 8.9% in patients with PAD without CAD (HR 1.79, 95% CI: 1.62-1.99; p < 0.001) as were individual components of the composite. ALI occurred in 1.6% of patients with PAD and CAD and 1.7% of patients with PAD without diagnosed CAD (HR 0.92, 95% CI: 0.69-1.22; p=0.55). Major bleeding occurred in 1.8% of patients with PAD and CAD and 1.5% of patients with PAD without diagnosed CAD (HR 1.21, 95% CI: 0.91-1.60; p=0.19) (Figure 1) .
After adjustment for baseline variables, patients with PAD enrolled with CAD had statistically significantly higher rates of the primary composite endpoint (HR 1.50, 95% CI: 
Effect of ticagrelor versus clopidogrel in PAD and CAD
In the subset of 4032 patients with CAD, 2019 were randomized to ticagrelor and 2013 to clopidogrel. The baseline characteristics of these patients in the two randomized arms were well matched (Supplemental Table 1 Other key secondary and composite endpoints, including coronary revascularization, were also not significantly different between treatment groups, although there was a significant interaction for ticagrelor for history of coronary or carotid revascularization and for history of coronary stent implantation ( Table 3) .
The primary safety endpoint of TIMI major bleeding occurred in 1.7% of patients treated with ticagrelor versus 1.8% of clopidogrel-treated patients (HR 1.06, 95% CI: 0.66-1.69; p=0.81). Fatal bleeding, intracranial bleeding, and TIMI minor bleeding were all low frequency events and not significantly different between treatment groups (Table 4) .
There was no heterogeneity of efficacy or safety treatment effects observed in patients enrolled with prior MI, prior PCI, or prior CABG (Supplemental Table 2 ).
In the primary analyses, a nominally significant interaction was observed for the treatment effect for the primary endpoint in the group of patients with PAD with a prior coronary stent at randomization compared with those without a stent (p for interaction = 0.03). 11 Among 1964 patients with PAD and a history of a coronary stent, there was a trend toward benefit with ticagrelor for the composite rate of cardiovascular death, MI, or ischemic stroke versus clopidogrel (13.8% vs 16.8%, HR 0.82, 95% CI: 0.65-1.03; p=0.09). Other secondary and safety endpoints are presented in Supplemental Table 3 .
Discussion
EUCLID enrolled patients with symptomatic lower extremity PAD either based on a prior history of limb revascularization or a low ABI indicating hemodynamic compromise in the lower extremity. In this patient population, 29% had a prior history of CAD defined as a prior MI or coronary revascularization. The subgroup with PAD and CAD had a markedly elevated risk of major cardiovascular events indicating that polyvascular disease is a potent mediator of increased risk, as previously described, despite a higher use of cardioprotective medications compared with those who had PAD only. 3 There was no difference in ALI between groups, suggesting that a history of CAD is not a driver of ALI independent of PAD. The primary efficacy and safety endpoints occurred with similar frequency in patients with PAD and CAD treated with ticagrelor or clopidogrel. This finding was consistent in patients with PAD who entered the study with a prior history of MI, PCI, or CABG.
Patients with PAD without CAD had an annualized cardiovascular death, MI, or stroke incidence of 3.3%, which is considerably elevated compared with a healthy, agematched population. 13, 14 Patients with PAD without a history of CAD are often not recognized as having a systemic cardiovascular condition and have been well described as receiving less intensive risk-reduction therapies. [15] [16] [17] In EUCLID, this phenomenon was also observed: at baseline, patients with PAD and no history of CAD had a lower use of antiplatelet therapies, statins, angiotensin converting enzyme and angiotensin receptor blocker drugs. This observation underscores the need for continued education of both patients with PAD and their providers in the need for appropriate use of secondary prevention strategies. 18 Patients with symptomatic PAD are a high-risk group for cardiovascular morbidity and mortality. The composite endpoint of cardiovascular death, MI, or ischemic stroke occurred in 15.3% of patients with PAD and CAD, a 6.4% absolute increase compared with PAD without CAD. Concomitant CAD increases the rate of MI, ischemic stroke, and cardiovascular death. After adjustment for baseline differences, the risk of MI was more than twofold higher in patients with symptomatic PAD and CAD than PAD without diagnosed CAD. These findings underscore the importance of identifying polyvascular disease in the clinic to inform future cardiovascular risk.
An important question remaining regards treatment strategies to reduce risk and event rates in this population. In trials enrolling patients with ACS or prior MI, more potent antiplatelet therapy is more effective at decreasing cardiovascular events. The PLATO (PLATelet inhibition and patient Outcomes) trial used a dual antiplatelet strategy (in contrast to EUCLID in which monotherapy was investigated) and demonstrated a similar benefit of ticagrelor versus clopidogrel in patients with ACS with and without PAD. 9 However, owing to the higher risk of cardiovascular events in the PAD subgroup, a greater absolute benefit was observed in patients with versus without PAD. 9 In the PEGASUS-TIMI 54 (Prevention of Cardio vascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial, patients with a prior MI and PAD experienced a robust absolute risk reduction of 4.1% at 3 years with ticagrelor versus placebo, in which both groups were taking aspirin, relative to 1% for those without PAD. 10 In a post hoc analysis of patients with PAD enrolled in the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Manage ment, and Avoidance) trial, dual antiplatelet therapy with aspirin plus clopidogrel versus aspirin alone did not reduce the composite of cardiovascular events. 19 With this background in mind, the neutral effect of ticagrelor versus clopidogrel observed in the current analysis, even in patients with a prior history of CAD, indicates that potent platelet inhibition with monotherapy targeting the P2Y12 pathway did not result in additional clinical benefit in an outpatient population with PAD with or without CAD.
Study limitations
The EUCLID trial was not designed to specifically evaluate the use of ticagrelor in patients with symptomatic PAD and concomitant CAD. The limited statistical power available and the well-known potential confounding of post hoc analyses require caution and demonstrate the need for adequately designed and powered studies in this high-risk cohort. Differences in outcomes between patients with PAD and CAD versus PAD without diagnosed CAD should be interpreted within the context of between-group differences (Table 1 ) and multiple comparisons between groups. The EUCLID trial was an antiplatelet monotherapy trial; patients with PAD requiring dual antiplatelet therapy were excluded from this trial. Clopidogrel was an active comparator and has potent antiplatelet effects. Finally, patients who were homozygous for loss-of-function alleles to clopidogrel were excluded before randomization.
Conclusions
In patients with symptomatic PAD, concomitant CAD is associated with a heightened risk of cardiovascular events, even after adjusting for their extensive comorbidities. In these patients, ticagrelor did not reduce the primary composite endpoint of cardiovascular mortality, MI, or ischemic stroke compared with clopidogrel.
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